Making Continuous Glucose Monitoring More Accessible in Australia
Continuous glucose monitors (CGMs) can give people a clearer view of how glucose changes between meals, overnight, during exercise, and when medication is adjusted. For someone managing diabetes, that stream of information may reveal patterns that finger-prick testing misses. Cost, device availability, digital confidence, and access to follow-up care can still place CGM technology out of reach.
A pilot study of low-cost continuous glucose monitors in medically underserved populations could test whether affordable sensors are practical, acceptable, and clinically useful in Australian settings. The focus should extend beyond the device itself to include education, culturally safe care, connectivity, data privacy, and a reliable pathway from readings to treatment decisions.
This is a natural area for translational health research in Queensland, where metropolitan hospitals, community services, universities, and regional providers can work together. The Brisbane Diamantina network provides a relevant partnership context for moving evidence from research environments into care that benefits patients, families, carers, and communities.
Why Affordable Glucose Data Matters
CGMs measure glucose in interstitial fluid through a small sensor placed under the skin. Depending on the model, they provide readings through a phone app, reader, or scanning device. The information can help identify overnight highs, exercise-related lows, delayed rises after meals, and changes that might otherwise remain hidden.
For people experiencing financial hardship, unstable housing, disability, limited transport, or competing health concerns, the cost of sensors may be a substantial barrier. A cheaper option could support earlier intervention and better self-management, although affordability should never be treated as a substitute for clinical support. A low-cost monitor that is difficult to use or impossible to replace is unlikely to deliver lasting value.
Australia’s existing access arrangements also matter. Some people with diabetes may receive subsidised technology through the National Diabetes Services Scheme, while others may face eligibility limits or pay privately. A pilot should document these differences rather than assuming that every participant begins with the same access to supplies, smartphones, data, or specialist services.
Designing For Queensland Communities
A Brisbane-based pilot could include participants from outer metropolitan areas as well as communities across regional Queensland. Travel from Logan, Ipswich, or Moreton Bay to a tertiary service can be burdensome, while a participant in Mount Isa, the Darling Downs, or Far North Queensland may face long distances, workforce shortages, and patchy internet access. Remote monitoring must be designed around these realities.
The study should include Aboriginal and Torres Strait Islander health services from the start, with local leadership over recruitment, consent, communication, and data governance. A culturally safe approach may involve community-controlled services, Aboriginal health workers, plain-language resources, and time to build trust. It should also recognise that family involvement and community relationships can shape decisions about health technology.
Practical details can determine whether a sensor works in daily life. Heat, humidity, physical work, swimming, shift work, and contact sports may affect adhesion and comfort. Participants need clear guidance for charging devices, replacing sensors, managing alerts, and seeking help when readings do not match symptoms.
Building A Fair Pilot Study
A useful pilot should compare more than glucose metrics. Researchers can assess recruitment, sensor wear time, data completeness, usability, confidence in interpreting readings, hypoglycaemia events, and unplanned presentations. Measures of wellbeing, treatment burden, and satisfaction can show whether the technology fits real life rather than simply producing attractive graphs.
Eligibility criteria should reflect people who are often missed by research, including adults with type 2 diabetes who are not using intensive insulin therapy, people living in lower-income households, culturally diverse communities, and participants without reliable broadband. Researchers should avoid excluding someone simply because they have an older phone, limited English, or intermittent digital access.
The evaluation should include a clear comparison, such as usual glucose monitoring supported by structured education. It may also be useful to test two implementation pathways: one through a hospital diabetes clinic and another through general practice, community pharmacy, or an Aboriginal Community Controlled Health Organisation. That design can reveal which model is more feasible when specialist appointments are scarce.
Protecting Safety, Privacy, And Trust
A CGM reading is not a diagnosis. Sensors can lag behind blood glucose, lose connection, become inaccurate, or produce alerts that cause anxiety. Every participant should receive instructions on confirming unexpected results, recognising symptoms of hypoglycaemia and hyperglycaemia, and contacting a clinician. The pilot must have a documented escalation pathway for urgent concerns.
Data governance deserves equal attention. Glucose records may be stored in manufacturer platforms, cloud services, or research databases, sometimes across international jurisdictions. Consent materials should explain who can view the information, how long it will be retained, whether it may be linked with hospital records, and how participants can withdraw.
Researchers should report adverse events, skin reactions, device failures, missing data, and participant withdrawals transparently. If a sensor is subsidised for the study but becomes unaffordable afterwards, participants should be told what ongoing options exist. Trust is strengthened when the research team is honest about limitations and does not promise improved outcomes before they have been demonstrated.
Turning Findings Into Clinical Practice
Translation begins during study design, not after the results are published. Clinicians, diabetes educators, primary care teams, consumers, carers, health economists, procurement staff, and community organisations should help define the research question and the outcomes that matter. Brisbane Diamantina’s grant writing guide offers a useful reminder that a strong translational proposal must connect need, method, partnership, implementation, and measurable benefit.
If the pilot shows promise, the next stage could examine cost-effectiveness and clinical outcomes over a longer period. Important questions include whether affordable CGM reduces emergency presentations, improves time in range, supports medication adjustment, or helps people remain engaged with primary care. A health economist can compare sensor costs with potential savings from fewer complications and better-targeted treatment.
Implementation should also fit the Australian health system. Results may inform diabetes services, Primary Health Networks, state-funded programs, pharmacy partnerships, or future subsidy decisions. A scalable model might combine a lower-cost sensor with group education, telehealth, community-based review, and periodic clinician oversight rather than relying on specialist appointments alone.
Practical Priorities For The Research Team
A well-designed pilot can produce evidence that is clinically meaningful and useful to decision-makers. The following priorities can help keep the project focused on access, safety, and real-world adoption:
- Co-design recruitment and support materials with consumers, carers, Aboriginal and Torres Strait Islander representatives, and local health workers.
- Include participants from metropolitan, regional, and remote Queensland rather than treating Brisbane access as representative of the whole state.
- Provide loan phones, mobile data, chargers, or alternative readers where digital exclusion could affect participation.
- Train participants in sensor use, glucose interpretation, troubleshooting, and when to confirm a result with a finger-prick test.
- Measure affordability, device acceptance, data completeness, clinical outcomes, and participant wellbeing alongside time-in-range results.
- Establish a clinical escalation process and a plan for sensor replacement, adverse events, and post-study support.
- Publish findings in a form that can guide services, funders, clinicians, and communities—not only academic audiences.
A pilot built around these principles can show whether lower-cost CGM is genuinely accessible, rather than simply cheaper at the point of purchase. It can also identify which forms of education, follow-up, and technical support are essential for sustained use.
The next step is to bring together people with diabetes, community-controlled health services, primary care teams, endocrinologists, researchers, and health system partners to shape a fundable protocol. With transparent governance and strong local partnerships, Queensland can generate practical evidence about how continuous glucose monitoring might reach people who are least well served by current arrangements.
